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Abstract 
Background: Although mucosal sites such as the gut have been extensively studied, less is known 
about the immune cell composition of the human female genital tract, a surface through which HIV is 
transmitted. This study aimed to determine the frequency of immune cell subsets in endocervical and 
ectocervical tissue sections of HIV uninfected women. 
 
Methods: Six cervical explant tissue samples were obtained from women undergoing elective 
hysterectomies in Prince Mshiyeni Memorial Hospital and King Edward VII Hospital, Durban, South 
Africa. The tissues were dissected into 2mm blocks and mechanically digested and dissociated using 
the mouse spleen (m_spleen_01) program of the gentle-MACS Dissociator. B and T cell subsets 
phenotyping were quantified using flow cytometry.  
 
Results: Endocervix and ectocervix tissue was obtained from 4/6 recruited participants and two 
participants only had endocervix tissue available. Overall, T cell subsets (as marked by CD3+ and 
CD4+ subsets) were the most abundant cell population compared to B cells (as marked by CD19+ 
expression) in the cervix (45% vs. 4%, respectively). Although the overall frequency of B cells 
observed in both endocervical and ectocervical regions was low, the abundance of CD19+ cells was 
slightly higher in the endocervix (4%) compared to the ectocervix (2%). There was no significant 
difference in the frequencies of T cell populations (CD3+ and CD4+ cells) in the ectocervix and 
endocervix. The majority of CD4+ T cell co-receptors found in the cervix were CXCR4 (69%), 
followed by CD127 (67%), CXCR3 (66%) and CCR6 (63%). CCR5 was detected in 38%, while both 
CD25 and PD1 were expressed in 34% of CD4+ T cells. None of these CD4+ T cell co-receptors 
were significantly different in the ectocervix and endocervix, with an exception of CCR6 and PD1 
that showed a trend towards being elevated in the endocervix compared to ectocervix, p=0.067. There 
was no difference in frequencies of both B and T cells amongst women on hormonal contraceptives 
versus non-hormonal contraceptive users. 
 
Discussion: Although limited by sample size, our data suggest that the T cells (CD3 and CD4+) were 
more abundant than B cells in the endocervix. Compared to the ectocervix, the endocervix had 
slightly higher frequencies of CD4+ T cell receptors (CCR6, PD-1, CCR5, CD25) suggesting that 
endocervix might be a preferential region for HIV infectivity, replication and transmission.   
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Chapter 1: 
Introduction and Literature Review 
1.1 Introduction 
Sub-Saharan African is home to 14% of the world’s population but contributes a disproportionate 
70% of all the world’s human immunodeficiency virus (HIV) infection, with over 1000 new 
infections every day (Abdool Karim et al., 2010, Gómez-Olivé et al., 2013, UNAIDS, 2017). The risk 
for HIV infection in sub-Saharan Africa is skewed towards women, particularly young women 
between the ages of 15-24 years, with HIV prevalence in young women up to 3 times more compared 
to their young male counterparts (Figure 1.1) (UNAIDS, 2017, Abdool Karim et al., 2017). It is 
thought that young women become infected with HIV after fewer acts of unprotected heterosexual 
intercourse (Pettifor et al., 2005, Glynn et al., 2001) with transmission of HIV across mucosal 
surfaces in women being the most common route of HIV infection (Abdool Karim et al., 2010). 
 
 
 
Figure 1. 1. Map showing the disproportionate burden of HIV in young women in sub-Saharan 
Africa. Adolescent girls and young women between the ages of 15-24 years in eastern and southern 
Africa up to eight times more HIV infection compared to their male peers. Figure adapted from 
(Abdool Karim et al., 2012). 
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The mucosal epithelium of the female genital tract (FGT) is the first line of defence against pathogen 
entry. Despite this, the vagina and cervix remain vulnerable to HIV infection (Hladik and Hope, 
2009). Studies have suggested the cervix is the most vulnerable region, with the endocervix being a 
preferential region for HIV replication compared to the ectocervix (Lee et al., 2015, Trifonova et al., 
2014). Also, the endocervix is lined with a more vulnerable single-cell, simple columnar epithelium, 
while the ectocervix is lined with a stronger multi-layered squamous epithelium (Critchlow et al., 
1995, Gray-Swain and Peipert, 2006, Hwang et al., 2011). A few studies have assessed the frequency 
and distribution of resident immune cells in the human cervix, with T cells being the more dominant 
population compared to B cells. Several studies showed that CD8+ T cells were the most abundant T 
cell population than CD4+ T cells in the human cervical mucosa (Givan et al., 1997, Pudney et al., 
2005, Saba et al., 2010). In contrast, macrophages (expressed by CD14+ cells and CD103 CD11b+ 
CX3CR1+ DC-SIGN+ dendritic cells (DCs), were the most dominant population in the human 
cervical mucosa (Trifonova et al., 2014). It was further shown that the endocervix has a greater 
abundance of HIV target cells such as the CD4+ T cells with post-menopausal women illustrated as 
more vulnerable to HIV infection (Trifonova et al., 2014). This suggests that each region of the FGT 
differs and one region may be more preferential for HIV due to the abundance of HIV target cells. 
However age, hormones and contraceptive usage play a vital role in immune cell abundances and the 
structure of both the ectocervix and endocervix (Trifonova et al., 2014, Reis Machado et al., 2014). 
Although few studies have defined B cell, T cell and DC population within cervical mucosa, no study 
has looked at the proportions and distribution of CD4+ co-receptors and their link with HIV 
infectivity. 
 
For decades, several studies on humanized mice were used to advance understanding of HIV 
transmission (Olesen et al., 2011, Denton et al., 2008, Wheeler et al., 2011) while others used 
macaque SIV models to understand SIV (Simian Immunodeficiency Virus) susceptibility (Zhang et 
al., 1999, Miller et al., 2005, Haase, 2010). Not only did the findings of these studies fail to fully 
explain the mechanism by which HIV may be transmitted to humans, but several limitations were also 
noted. These include low immune cell numbers and different cellular response to chemokines secreted 
by mouse epithelial cells (Hladik and McElrath, 2008, Policicchio et al., 2016). Furthermore, other 
approaches have also been used to investigate immune responses at the FGT. These methods include 
the use of cytobrushes and cervicovaginal lavage obtained from cervico-vaginal surfaces, in 
combination with flow cytometry and Luminex technology (Grivel and Margolis, 2009, Liebenberg et 
al., 2011, Roberts et al., 2012). As an alternative, human cervical samples have been used to assess 
women’s susceptibility to HIV transmission (Saba et al., 2010, Grivel and Margolis, 2009). Human 
cervical explants enable the study of HIV infection and cellular or antibody responses in intact tissues, 
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rather than in single cells, which more closely resembles what happens in vivo (Grivel and Margolis, 
2009). 
 
Taking all this into consideration, it is clear an extensive understanding of the relationship between 
abundance of genital immune cell subsets and transmission of HIV is warranted. Specifically, there is 
a need to better characterise the innate and adaptive immune cells in the endocervix and ectocervix of 
healthy women. Characterizing the abundance and distribution of the major immune cells within the 
different regions can help associate a specific region with infectivity and be able to link inflammation 
of the genital tract to an increased recruitment of HIV target cells. 
 
1.2 Literature Review 
1.2.1 The Female Genital Tract 
The FGT is a unique system that has an ability to balance defence against invading pathogens with 
tolerance towards reproductive components such as sperm, embryo and foetus (Nguyen et al., 2014). 
It is a complex structure composed of keratinocytes linked by different proteins that provide a 
biological barrier, separating the extrinsic factors from the lymphatic and circulatory systems (Wira et 
al., 2015). It consists of the stratified squamous epithelial introitus (vaginal opening), the vaginal 
mucosa and the cervix (Lee et al., 2015, Pudney et al., 2005). The cervix is a cylinder-shaped neck of 
tissues situated at the lowermost part of the uterus and connects the uterus and vagina (Figure 1.2) 
(Nguyen et al., 2014).  
 
The cervix consists of the ectocervix, endocervix and the squamocolumnar junction known as the 
transformation zone (Danforth, 1983). These sites differ structurally, with the vagina and ectocervix 
characterised by a multi-layered non-keratinised stratified squamous epithelium (Petrova et al., 2013) 
while the mucosa of the endocervix is made up of a single layer columnar epithelium and within the 
transformation zone, squamous epithelial cells transform to columnar epithelial cells (Reis Machado 
et al., 2014, Hladik and Hope, 2009). The transformation zone usually withdraws into the endocervix 
by the onset of menopause (Singer, 1975). The endocervix is reliant on mucus, tight and adherens 
junctions in the epithelium while the ectocervix is reliant on the multiple layers of squamous 
epithelium as a physical barrier of protection against invading pathogens, respectively (Nguyen et al., 
2014). Although these layers provide a first line of defence against invading pathogens, the potentially 
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protective superficial layer is continuously sloughed off, which may result in vulnerability to 
ascending infections such as HIV (Wira et al., 2005a).  
 
 
Figure 1. 2. Characterisation of the female genital tract mucosa. The mucosa of the lower FGT, which 
is made up of the vagina and ectocervix, is defined by a multi-layered squamous epithelium that is 
held together by tight junctions and houses various immune cells such as dendritic cells, T cells and 
macrophages. The upper FGT is defined by a single layer of columnar epithelium which houses 
lymphoid aggregates composed of B and T cells. A healthy FGT is also dominated by antimicrobial 
peptide producing lactobacilli. Figure adapted from (Nguyen et al., 2014). 
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The epithelium in the FGT secretes a protective moisture, providing a hydrophilic layer of 
glycoproteins called glycocalyx and a hydrophobic glycoprotein mucus which aids in trapping 
pathogens, thereby preventing ascending infections (Gipson et al., 1997, Vigil et al., 2009, Reis 
Machado et al., 2014). Genital epithelial cells also produce various antimicrobial peptides and 
proteins into the cervicovaginal fluids, express toll-like receptors (TLRs) and secrete inflammatory 
cytokines in response to antigen binding (Petrova et al., 2013, Wira et al., 2005a). Both the vagina and 
ectocervix are the primary sites exposed to male seminal fluids and are more prone to invading 
pathogens compared to the endocervix and transformation zone (Shattock and Moore, 2003, Miller et 
al., 1992, Pudney et al., 2005). However, the endocervix and transformation zone are thought to be the 
sites where HIV is most likely to penetrate and access the high number of target cells available 
(Hladik and Hope, 2009, Lee et al., 2015, Miller et al., 1992, Kell et al., 1992, Pudney et al., 2005, 
Shattock and Moore, 2003).  
 
1.2.2 Mucosal immune system of the female genital tract  
The epidermis of the FGT is home to a small number of different cell types, with keratinocytes being 
the most abundant (Lee et al., 2015, Wira et al., 2005a). In a healthy FGT, Langerhans cells (LCs) are 
found within the squamous epithelium and express cluster of differentiation (CD)-1a. LCs have the 
ability to reach into granulosum and stratum corneum to present foreign antigens and initiate the 
immune responses (Hickey et al., 2011). Other cells present within the sub-milieu of tissue are DCs, 
the primary antigen presenting cell (APC) responsible for the induction of host immune response that 
can be tolerogenic or antigen specific adaptive response (Lee et al., 2015, Amjadi et al., 2014). DCs 
have been shown to express the HIV binding co-receptors CCR5, as well as a C type lectin DC-SIGN 
which mediate HIV entry into DCs (Petrova et al., 2013, Wu, 2008).  
 
The epithelial lamina propria of the vaginal mucosa also contains an array of cells, which include 
different immune cells such as the granulocytes and T cells, while B cells, macrophages and 
monocytes are present in much smaller numbers (Givan et al., 1997, White et al., 1997). Although 
relatively few compared to blood, the cervicovaginal mucosa contains leukocytes, with CD8+ T cells 
being the most abundant, followed by small numbers of CD4+ T cells, CD45+ neutrophils, CD56
bright 
NK cells, CD68+ macrophages and CD1a+ immature DCs (Lee et al., 2015, Pudney et al., 2005). B 
cells (CD19+ and CD20+ B cells) are also said to be located around these lymphocyte clusters in 
follicle-like structures of the cervicovaginal mucosa (Lee et al., 2015, Johansson et al., 1999). When 
comparing immune cell distribution between the ectocervix and endocervix; T and B cells were found 
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more abundant in the ectocervix while there was no difference in numbers of NK cells, CD14+ 
macrophages and DCs (Trifonova et al., 2014). With high levels of CD8+ T cells and antigen 
presenting cells in the endocervix, it is thought to be the site where initial cellular response against 
pathogens occur (Trifonova et al., 2014, Lee et al., 2015). However, due to the large quantities of 
CD4+ T cells, macrophages and DCs present in the endocervical mucosa and transformations zone, 
these regions are also thought to be more vulnerable to HIV infection compared to the ectocervical 
and vaginal mucosa (Pudney et al., 2005, Trifonova et al., 2014). The FRT also plays residence to a 
variety of CD4+ T cells subsets which are defined by the co-receptor present (eg. CCR6, CXCR4) on 
the CD4+ T cell (Lee et al., 2015).  
 
1.2.3 CD4+ T cell co-receptors 
 
One of the most studied co-receptor of the CD4+ T cell CCR5 which is the co-receptor for R5 strains 
of the HIV virus (HIV-1, HIV-2) (Oppermann, 2004). The gp120 envelope of the HIV virus binds 
onto the CD4 receptor of the CD4+ T cell and following a conformational change the gp120 protein is 
able to bind onto the CCR5 co-receptor thus initiating the first step in HIV infection (Alkhatib, 2009). 
Mutations of the CCR5 co-receptor can lead to resistance against the HIV virus (Quillent et al., 1998). 
Studies have found that when compared to peripheral blood, CD4+ T cells in the genital significant 
express more CCR5 (Iyer et al., 2017). Another important CD4+ T cell co-receptor is CXCR4 which 
also takes part in the binding of X4 tropic HIV virus (Poveda et al., 2007). HIV binding to CXCR4 is 
for the most similar to R5 strains in which gp120 protein binds first to CD4 and then to CXCR4 and 
CXCR4 is functionally expressed on cancer cells, playing a role if proliferation and migration 
(Alkhatib, 2009). 
CCR6 expression is commonly a defining marker of Th17 cells which perform both roles 
inflammation and migration (Yamazaki et al., 2008). Th17 cells additionally play a role in 
maintaining vaginal epithelial integrity; therefore a reduction may lead to genital inflammation which 
could further aid viral replication (Stieh et al., 2016). Studies have aslo shown that these Th17 cells 
are susceptible to HIV and are depleted early within the cervix of HIV infected patients (Sallusto et 
al., 2012, Weaver et al., 2013). The functionality of CD4+ T cells expressing CXCR3 is trafficking 
and migration of T cells to lymphoid compartments where they interact with antigen presenting cells 
which can lead to the production of effector and memory T cells (Groom and Luster, 2011). CD4+ T 
cells expressing CXCR5 are associated with follicular B helper T cells which aid in B cell 
communication and the CD127 and CD25 markers are associated with regulatory cells which are 
differentially depleted during HIV infection (Moser, 2015, Dunham et al., 2008). PD-1 expression on 
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CD4+ T cells is a marker for cell exhaustion and plays a role in death and regulation of T cells (Riley, 
2009).   
 
 
1.2.4 Microbial environment of the female genital tract and HIV risk 
The cervicovaginal mucosa is a non-sterile environment with roughly 10
9
 microorganisms per 
millilitre present (Quayle, 2002, Mirmonsef et al., 2011). The microbial community of healthy women 
is generally considered to be dominated by Lactobacillus species. The Lactobacillus spp. are thought 
to provide protection by lowering the vaginal pH of the lower genital tract through lactic acid 
production, various bacteriostatic and bactericidal compounds such as hydrogen peroxide (H2O2), and 
through competitive exclusion of other organisms (Figure 1.3) (Ravel et al., 2011, Reis Machado et 
al., 2014, Klebanoff and Coombs, 1991). A number of different Lactobacillus spp. have been 
described in healthy genital tracts although the most frequent and abundant of these are L. crispatus, 
L. gasseri, L. jensenii and L. iners, however, not all Lactobacillus species are equally protective, with 
L. iners found in both healthy and bacterial vaginosis (BV) affected vaginal environments (Ravel et 
al., 2011, Petrova et al., 2013, Gootenberg et al., 2018). These bacteria are also classified into 
community state types (CST) according to which is most dominant in the microbiota, CST I: L. 
crispatus, CST II: L. gasseri, CST III: L. iners, CST V: L. jensenii, CST V: anaerobic dominance 
(Gootenberg et al., 2018, Ravel et al., 2011). A genital environment, dominated by Lactobacillus 
species, has been associated with healthy pregnancy outcomes, lack of abnormal vaginal symptoms 
and urogenital disease and reduced risk for several sexually transmitted infections (STIs), including 
Human papillomavirus (HPV) and/or HIV (Petrova et al., 2013, Reis Machado et al., 2014, Ness et 
al., 2005). Replacement of commensal Lactobacillus spp. with commensal gram negative bacterial 
pathogens may lead to BV, a microbial dysbiosis often resulting in vaginitis and discharge and 
increased HIV risk (Kenyon et al., 2013, Macklaim et al., 2013, Gosmann et al., 2017). 
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Figure 1. 3. General overview of the mechanism by which Lactobacilli species prevent invading 
pathogens (such as HIV) and overgrowth of strict anaerobic bacteria in the lower female genital tract. 
A Lactobacillus dominated vaginal microbial community has long been associated with health, by 
inhibiting the colonization of genital pathogens through (1) the production of lactic acid and H2O2, (2) 
competing with other microorganisms for epithelial receptor sites, (3) variety of inhibitory agents 
such as bacteriocins, (4) Lectin mediated binding and capture of HIV and (5) by regulating the 
immune response. Reduction in Lactobacilli spp. may lead to diverse microbial communities linked 
with bacterial vaginosis and increased risk of HIV infection, likely via genital inflammation (red 
colour in epithelium) and recruitment of target cells. Figure adapted from (Petrova et al., 2013).  
 
BV is the most common cause of vaginal discharge in women of reproductive age, although its 
prevalence varies considerably between ethnic groups. The etiology of BV is not known although it 
has clearly been associated with sexual activity (Kumar et al., 2011). Reduction in Lactobacilli 
species is generally accompanied by the intense overgrowth of commensal vaginal anaerobic bacteria, 
which can reach densities 100 to 1000 times higher than found in healthy vaginas, and display 
significantly increased bacterial diversity (Macklaim et al., 2013). Cultures of organisms from the 
genital tract of women with BV typically yields a spectrum of facultative anaerobic commensals, 
including Gardnerella vaginalis, Atopobium vaginae, Eggerthella spp., Prevotella spp., BVAB2 
(Clostridia-like bacteria), Megasphaera type 1, Mobiluncus spp, Ureaplasma urealyticum and 
Mycoplasma hominis (Shipitsyna et al., 2013). An absence of Lactobacillus species, combined with 
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the presence of G. vaginalis, A. vaginae, and/or Prevotella spp. (Shipitsyna et al., 2013) have been 
suggested to be highly accurate indicators of BV.  
BV has been associated with increased genital inflammation (Anahtar et al., 2015), and an increased 
risk for HIV infection (Figure 1.3) (Cohen et al., 2012). A recent study by Anahtar et al. (2015) 
demonstrated that high BV-associated bacterial communities were associated with increased 
proinflammatory cytokine levels due to APCs sensing bacterial products via TLR6 which leads the 
activation of (NF)-κβ pathway that ultimately results in inflammation and target cell recruitment 
(Anahtar et al., 2015). Due to the complexity of BV, which is often different syndromically, some 
studies have shown BV to be associated with the upregulation of proinflammatory cytokines while 
others have found BV to be associated with the downregulation of certain cytokines (Passmore et al., 
2016, Masson et al., 2014, Kyongo et al., 2012, Deese et al., 2015). Proteomics shows that along with 
BV being associated with increases in cytokines and cytokine receptors, BV is also associated with 
changes in proteins that are linked to the breakdown of the mucosal barrier and mucus alterations 
(Passmore et al., 2016, Borgdorff et al., 2016). Due to its inflammatory nature, BV has been 
associated with an increased risk of acquiring an STIs, including Chlamydia trachomatis, 
Trichomonas vaginalis, herpes simplex virus type 2 (HSV-2) and Neisseria gonorrhoea (Al-Harthi et 
al., 1999, Abbai et al., 2016).  
 
1.2.5 Impact of hormonal changes in the female genital tract 
The FGT experiences progressive anatomic changes that are controlled by oestrogen and progesterone 
from birth through menopause (Beagley and Gockel, 2003). Immune cells in the FGT, including 
epithelial cells, macrophages, dendritic cells and T cells, are regulated by hormones such as oestrogen 
and progesterone which vary during the menstrual cycle (Polis et al., 2014). A study investigating the 
changes in immune cell numbers during different stages of the menstrual cycle found that levels of 
CD4+, CD8+ T cells and B cells were higher in the ectocervix compared to the endocervix in pre-
menopausal women (Trifonova et al., 2014). Only CD4+ T cells remained abundant in post-
menopausal women (Trifonova et al., 2014). There were no significant differences in densities of 
CD14+ macrophages, DCs and LCs within the vagina and cervix when comparing the luteal and 
follicular phase of the menstrual cycle (Lee et al., 2015, Pudney et al., 2005). Chandra et al. (2013) 
showed that women with high levels of progesterone [particularly those using depo-
medroxyprogesterone acetate, (DMPA)] had significantly higher numbers of activated T cells and 
macrophages expressing CCR5 compared to their non-progesterone users. In contrast, Mitchell et al., 
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(2014) found no difference in density or numbers of T cells or CCR5
+
 HIV-1 target cells in the lower 
reproductive tract of women using DMPA compared to non-HC users (Mitchell et al., 2014). 
Oestrogen and progesterone have been shown to regulate the thickness of the genital mucosal barrier 
during the reproductive cycle in women (Beagley and Gockel, 2003, Fahey et al., 2008). Increased 
levels of oestrogen have been shown to contribute to protection against invading pathogens by 
increasing the thickness of the vaginal epithelium and production of cervical mucous, as well as being 
able to aid in the growth of beneficial commensal bacteria such as Lactobacilli (Morrison et al., 2015, 
Wira et al., 2015, Petrova et al., 2013). Although oestrogen may have potential protective effects, data 
from several studies suggest that high levels of progesterone may have adverse effects on the FGT, 
resulting in increased risk for HIV infection (Wieser et al., 2001, Wira et al., 2011, Miller et al., 2000, 
Ildgruben et al., 2003). Studies have shown that the mucosal barrier is compromised during the luteal 
phase, a phase characterized by high progesterone levels (Wira et al., 2015). It has been shown that 
high-dose progesterone decreases the integrity and thickness of the genital mucosal barrier in women 
and the density of intracellular junction proteins in the stratified epithelial layer (Ildgruben et al., 
2003, Chandra et al., 2013, Miller et al., 2000, Wira et al., 2011). In contrast, other studies have found 
no association between progesterone and genital epithelial barrier integrity (Chandra et al., 2013, 
Mitchell et al., 2014). In non-human primates, high-dose progesterone is commonly used in the 
simian immunodeficiency virus (SIV) vaginal challenge model, specifically because it thins the 
vaginal epithelium and significantly increases the efficiency of vaginal transmission (Abel et al., 
2004, Trunova et al., 2006, Wieser et al., 2001, Marx et al., 1996). Decreased genital barrier function 
might facilitate more efficient contact between HIV target cells within the cervicovaginal mucosa and 
HIV particles entering the vaginal lumen. 
 
1.2.6 Impact of inflammation on the female genital tract 
Exploring mucosal risk factors in the FGT is critical for understanding STI/HIV susceptibility. 
Genital inflammation is the best biological correlate of HIV risk that has been described to date and if 
elevated prior to infection, has been associated with an approximately three-fold higher risk of 
acquiring HIV (Masson et al., 2015). Although the mechanisms to explain why some people have 
comparatively high levels of genital inflammation while others do not, are not fully understood, the 
likely drivers of genital inflammation are BV and STIs (Masson et al., 2015). In the CAPRISA 004 
1% tenofovir microbicide trial, women who acquired HIV during the trial had significantly elevated 
genital tract inflammatory markers (such as MIP-1α, MIP-1β, IL-8, and IP-10) prior to HIV infection, 
independent of study arm and age (Masson et al., 2015). It was further demonstrated that genital 
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inflammation reduced the effectiveness of 1% tenofovir in women, even in those with high adherence 
to the drug (McKinnon et al., 2018). Inflammation is needed for the clearance of infection, however, it 
can also lead to the disruption of infected epithelial barriers, which then facilitates access to target 
cells deep in the tissue (Passmore et al., 2016, Mcgee et al., 1999, Svanborg et al., 1999). Several 
studies showed decreased functionality of the epithelial barrier in the FGT of women was associated 
with elevated levels of proinflammatory cytokines (Passmore et al., 2016, Arnold et al., 2016). 
Furthermore, the detection of either MIP-1α or MIP-1β in CVL samples was associated with >3 fold 
increased odds of HIV infection (Masson et al., 2015). An ex vivo study using postmenopausal 
ectocervical tissue showed a strong association between genital inflammation and HIV replication 
(Reis Machado et al., 2014, Rollenhagen and Asin, 2011). Taken together, these data shows that an 
inflammatory environment favours HIV acquisition in women, regardless of the cause (Passmore et 
al., 2016). 
 
1.2.7 Female genital tract and sexually transmitted co-infections 
STIs, such as human papillomavirus (HPV), Neisseria gonorrhoea, Mycoplasma genitalium and 
Chlamydia trachomatis, can lead to reproductive complications and increased HIV susceptibility 
(Passmore et al., 2016, Laga et al., 1993, Mlisana et al., 2012). The most common impact that STIs 
have on the FGT is inflammation due to upregulation of pro-inflammatory cytokines and immune cell 
recruitment (Passmore et al., 2016, Fichorova et al., 2001). The presence of Mycoplasma genitalium, 
Chlamydia trachomatis and Neisseria gonorrhoea and the resultant increase in levels of IL-1β, IL-6, 
IL-8 and soluble CD40L was associated with increased risk of acquiring HIV (Passmore et al., 2016, 
Masson et al., 2014). HSV-2 has also been associated with elevated levels of DC-SIGN+ DCs and 
CCR5+ T cells and ulcerative lesions that affect the epithelial barrier and increases HIV susceptibility 
of the FGT. Furthermore, STIs can also affect vaginal health by displacing the healthy Lactobacillus 
population and altering the vaginal pH, resulting in overgrowth of BV associated organisms and 
increased HIV susceptibility (Petrova et al., 2013).  
 
1.2.8 HIV prevention strategies in the female genital tract 
The development of an effective HIV prevention tool for women is listed as a high research priority to 
achieve the goals set out by UNAIDS in its Fast-Track strategy to end the epidemic by 2030 
(UNAIDS, 2017). Currently, the most common form of prevention used is male and female condoms, 
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which act as effective barriers against HIV and other STIs (Arkell, 2016). The reasons condoms are 
the preferred method is that unlike contraceptives and other drugs, there are no adverse side effects 
other than rare latex allergies, and are effective against pregnancy and STIs (Cohen et al., 2011, 
Arkell, 2016). Female condoms, although still debatable with a partner, may offer women more 
control and power in terms of usage as compared to having to negotiate the use of a male condom 
(Arkell, 2016, Cohen et al., 2011). However, not many women use the female condom due to the lack 
of awareness of the product, poor basic knowledge and skills to insert and remove it properly, poor 
acceptance by both females and male partners, and relatively higher cost of this method (Arkell, 2016, 
Cohen et al., 2011). 
 
Over the past decade, three major trials (Abdool Karim et al., 2010, Baeten et al., 2012, Thigpen et al., 
2012) have demonstrated the prevention benefit of the prophylactic use of antiretroviral (ARV) drugs 
in women, with the CAPRISA 004 trial demonstrating moderate effectiveness in preventing HIV 
infection in women who used the intravaginal tenofovir (TFV) gel consistently (Abdool Karim et al., 
2010). Although product adherence was a crucial factor for effective HIV pre-exposure prophylaxis 
(PrEP), even with high adherence, protection was modest, underscoring a role for other biological risk 
factors (Marrazzo et al., 2015, Van Damme et al., 2012, Baeten et al., 2016). Tenofovir, commonly 
used as a component of ARVs, has been most extensively studied in efficacy trials for PrEP. 
Regardless of mode, the efficacy of tenofovir depends on cellular transportation and the enzymatic 
conversions, while tissue permeability and the dynamics of the vaginal environment are also crucial in 
the FGT (Taneva et al., 2015, Nixon et al., 2014). Intracellularly, TFV undergoes phosphorylation to 
the active metabolite, tenofovir diphosphate (TFV-DP), that compete with intracellular adenosine 
triphosphate (dATP, which is elevated in activated cells) to block HIV replication (Andrei et al., 2011, 
Suo and Johnson, 1998, Nixon et al., 2014). More recently, non-Lactobacillus spp. dominance of the 
vaginal microbiota, more specifically anaerobic BV-associated bacteria such as G.vaginalis, has been 
proposed as a potential contributor to the inability of topical TFV to protect women from HIV 
infection (Klatt et al., 2017, Hillier et al., 2017), an effect not found with oral TFV-based PrEP 
(Heffron et al., 2017).  
 
Although both studies showed a negative correlation between tenofovir levels and BV-linked bacteria, 
several limitations were also noted. For example, these studies used data collected at single random 
time points, with bacterial proteins (CAPRISA 004 study) and Nugent score (the FAME programme) 
used to identify vaginal bacterial community groups. In addition, the biodegradation of tenofovir was 
only shown in vitro, but this may not replicate in in vivo conditions. Taking all this into consideration, 
it is clear an extensive understanding of the relationship between vaginal microbiota, genital 
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inflammation, host and PrEP efficacy are warranted. It is also important that the mucosal micro-
environment must be understood to complement research on PrEP. Development of drugs that are not 
affected by environmental and host factors may lead to more consistent efficacy of PrEP in setting 
with imperfect drug adherence and high HIV incidence rate.  
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1.3 Aim and Objectives 
 
Rationale 
HIV transmission mostly occur across the mucosal surface of the female genital tract The vaginal and 
cervical mucosa is thought to serve as a discrete site for HIV infection, replication and pathogenesis 
by providing the virus with a steady supply of susceptible target cells. It was found that T 
lymphocytes are more prolific than B cells in the human cervix and that CD8
+
 T cells outnumber 
CD4
+
 T cells in these sites. However, very few studies have looked at the frequencies of local T and B 
cells in different regions within the human cervix. 
 
Aim:  
 To determine the frequency and anatomical distribution of immune cell subsets in 
endocervical and ectocervical tissue sections of HIV uninfected women. 
 
Objectives:  
 To characterize the distribution and phenotype of T cell and B cell population in endocervical 
and ectocervical tissue sections of HIV uninfected women. 
 To compare the availability of immune cell subsets in women using hormonal contraceptives 
to non-hormonal contraceptive users.  
Hypothesis: 
The ectocervix will have a greater abundance of immune cells compared to the endocervical region. 
In addition, women using hormonal contraceptives will have higher numbers of immune cells in their 
cervix compared to non-hormonal contraceptive users. 
  
16 
 
Chapter 2: 
Frequency and Phenotype of Immune Cell Subsets in different regions of 
the Human Cervix: Implications for HIV Susceptibility 
 
2.1 Introduction 
The mucosal epithelium of the lower FGT provides the first line of defense against pathogen entry 
and mediates the initial host immune response against STIs, including HIV (Kaushic, 2011, Wira et 
al., 2005a, Wira et al., 2005b). In addition, this is the surface through which HIV is transmitted from 
an HIV infected women to her sexual partner (Yi et al., 2013). Furthermore, the vaginal and cervical 
mucosa is thought to serve as a discrete site for HIV replication and pathogenesis by providing the 
virus with a steady supply of susceptible target cells (Nguyen et al., 2014). Although several studies 
have defined the composition of mucosal immune cells in the gut and lungs (Givan et al., 1997, 
Pudney et al., 2005, Saba et al., 2010), very little is known about immunity in the FGT.  
 
Several approaches have been used to investigate immune responses at the FGT. These methods 
include the use of humanized mice, macaques, cytobrushes and CVL obtained from cervico-vaginal 
surfaces, in combination with flow cytometry and Luminex technology (McKinnon et al., 2014, 
Policicchio et al., 2016, Hladik and McElrath, 2008, Grivel and Margolis, 2009, Liebenberg et al., 
2011, Roberts et al., 2012). However, these studies have limitations such as the use of single cells for 
flow cytometry analysis, low immune cell numbers, different cellular responses to chemokines 
secreted by mouse epithelial cells and poor translation of non-human primate discoveries into human 
studies. As an alternative, human cervical samples have been used to assess women’s susceptibility to 
HIV transmission (Givan et al., 1997, Trifonova et al., 2014). Cervical explants enable the study of 
HIV infection and cellular or antibody responses in intact tissues, rather than in single cells, which 
more closely resembles what happens in vivo (Grivel and Margolis, 2009). In addition, the epithelial 
lamina propria of the vaginal mucosa also contains an array of cells including T cells, B cells, resident 
phagocytes, macrophages and monocytes to provide both humoral and cell-mediated immunity 
(Givan et al., 1997, White et al., 1997). 
  
T lymphocytes have been shown to be more abundant than B cells in the human cervix and that CD8
+
 
T cells outnumber CD4
+
 T cells in these sites (McKinnon et al. 2014). Another study found that 
CD14+ macrophages, which is comprised of CD103 CD11b+ CX3CR1+ DC-SIGN+ DCs, were the 
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most abundant cells in the human cervical mucosa (Trifonova et al., 2014). Although these studies 
show proportions of cells in the cervical mucosa, very few studies have looked at the abundance of 
local T and B cells in different regions within the human cervix. This study determined the frequency 
of immune cell subsets with a particular focus on CD4 T cell co-receptors, in endocervical and 
ectocervical tissue sections of HIV-uninfected women. Characterizing the abundance of major 
lymphoid cells and CD4 co-receptor subsets within the cervix and their localization in different 
anatomical regions can help associate the abundance of vulnerable cells with HIV infectivity and 
recruitment of HIV target cells based on the functionality of the immune cell. 
 
2.2 Methods and Materials 
2.2.1 Study Design 
This study included HIV-uninfected women undergoing elective hysterectomies at Prince Mshiyeni 
Memorial Hospital and King Edward VII Hospital, Durban, South Africa. Patients attended hospitals 
for various reasons, including early stage cancer, fibroids and abnormal bleeding. All laboratory 
manipulation of the cervical tissue was performed in the CAPRISA Mucosal Immunology Laboratory, 
Durban, South Africa. Written informed consent was obtained a day before surgery from women who 
were deemed mentally fit by study gynaecologist and obstetrician. Patients demographic and clinical 
data were collected a day before surgery using a structured questionnaire. Consenting women aged 18 
years and older, including post-menopausal, as well as hormonal contraceptive users, were enrolled in 
the study. Women with severely damaged cervical tissues, due to surgery or late stage cancer and high 
grade cervical intraepithelial neoplasia (CIN) patients, were excluded from the study. Ethical 
approvals were obtained from Prince Mshiyeni Memorial Hospital, King Edward Hospital, 
Department of Health (HRKM Ref: 214/18, NHRD Ref: KZ_201805_041) and the University of 
KwaZulu-Natal Biomedical Research Ethics Committee (BREC: Ref: BE218/17), respectively.  
 
2.2.2 Peripheral blood mononuclear cells for gating strategies 
Peripheral blood mononuclear cells (PBMCs) were used to compensate for voltages, spill-over of the 
antibody flourochromes and to establish gating strategies for all subsequent samples. Briefly, PBMCs 
were isolated from blood acquired from healthy donors using BD Vacutainer

 acid citrate dextrose 
(ACD) tubes (Becton Dickinson (BD), NJ, USA). The ACD tubes were centrifuged at 1600 
revolutions per minute (rpm) for 10 minutes (min) at room temperature without brakes to ensure 
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adequate layer separation. Once centrifuged, the plasma layer was removed and replaced with 2% 
FBS/PBS (2% Fetal bovine serum (Thermo Fisher Scientific, MA, USA) in phosphate buffered saline 
(Lonza Group, Basel, Switzerland)) also known as FACS wash buffer, to dilute blood sample. The 
diluted blood sample was carefully layered over 12 ml of Ficoll-Paque (Sigma-Aldrich, MO USA) in 
a 50 ml conical tube. The tube was centrifuged at 1400 rpm for 30min without brakes at 4
o
C. After 
centrifugation, the plasma layer was removed and the mononuclear cell layer was carefully transferred 
to a new 50ml conical tube with 40ml of 2% FBS/PBS. The tube was centrifuged at 1600 rpm for 10 
min at 4
o
C. After spinning, the supernatant was decanted and the pellet was resuspended in 10ml of 
R10 (RPMI 1640 (Lonza Group, Basel, Switzerland) media supplemented with FBS and 
penicillin/streptomycin (Thermo Fisher Scientific, MA USA) media. Fifty microliters of mononuclear 
cells in R10 media and 50µl of trypan blue were used to obtain a viable cell count. After counting, 
mononuclear cells in R10 media were centrifuged at 2000rpm for 6 min at 4
o
C and the supernatant 
was discarded. The pellet was resuspended in 2% FBS/PBS at 1ml per million cells, centrifuged and 
stained at 4
o
C for 60 minutes in the dark with the following markers: CXCR5-APC; PD-1-BV421; 
CXCR4-PE-Cy5; CXCR3-PE-Cy7; CD4-BV605; CD25-FITC; CD127-PE; CD19-Alexa Flour 700 
(BioLegend, CA, USA); Live/Dead aqua for Amcyan (Thermo Fisher Scientific, MA, USA); CD3-
APC-H7; CCR5-PerCp-Cy5.5; CCR6-BV650 (BD, NJ, USA). Compensation for voltages and 
spillover of the antibody flourochromes were performed and at least 1000,000 events were acquired 
using a FACSDiva flow cytometer (BD Immunocytometry Systems, NJ, USA). Gates differentiating 
negative and positive populations were set by fluorescence minus one (FMO) staining, which stains 
cells with all fluorochromes used in the experiment except one (Perfetto et al., 2004). Cell doublets 
were excluded using forward scatter-area versus forward scatter-height parameters and dead cells 
were excluded from the analyses. 
 
2.2.3 Human Cervical Tissue Collection and Preparation 
Hysterectomies were performed at Prince Mshiyeni Memorial Hospital and King Edward VII 
Hospital. After surgery, cervical tissue was cut from the uterus using a scalpel blade and forceps and 
placed into R15 transport media (containing RPMI 1640, FBS, Pen/Strep, Amphotericin B) and 
transported to the laboratory on ice within 3 hours from collection. In the petri dish, tissue was rinsed 
with new transport media (R15) and kept in solution at all times to prevent tissue from drying out. 
Excessive muscular tissue was trimmed with scalpels and forceps, being sure to limit handling of the 
epithelial layer. The endocervix and ectocervix were separated and the tissue epithelial layer was 
carefully dissected into 2mm blocks using biopsy punch. 
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2.2.4 Tissue block digestion and dissociation 
To prepare a single cell suspension, the dissected 2mm tissue blocks were subjected to mechanical 
digestion and dissociation. Briefly, the tissue blocks were placed into a C-tube (MACS Miltenyi 
Biotec, CA, USA) containing 40µl of collagenase solution (0.2g of collagenase IV powder (Thermo 
Fisher Scientific, MA, USA), 2ml of HBSS (Lonza Group, Basel, Switzerland), 8µl of DNase 1 
(Thermo Fisher Scientific, MA, USA) and 8ml of R10 media. The solution with tissue blocks was 
then mechanically digested and dissociated for 60 seconds using mouse spleen (m_spleen_01) 
program of the gentle-MACS Dissociator (MACS Miltenyi Biotec, CA, USA), as previously 
described (Trifonova et al., 2014). After dissociation, the cell suspension was incubated for 60 
minutes at 37C. Cells were collected by filtering through a 100µm cell strainer (MACS Miltenyi 
Biotec, CA, USA), into a new 50ml conical tube. Any material left after the filtering was discarded. 
During the optimization steps, C-tubes with suspended tissue blocks were allowed to digest and 
dissociate without using the gentle-MACS Dissociator and compared to those dissociated using 
gentle-MACS Dissociator. The frequency of cells was too low in those digested without gentle-
MACS Dissociator and the rest of the study was carried with mechanical digestion and dissociation.  
 
2.2.5 Tissue Staining and flow cytometry 
During subsequent rounds of digestion, the cell suspension was centrifuged at 1800 rpm for 5 minutes 
at 4
o
C and cell pellets were resuspended in labelled (endocervix and ectocervix, respectively) BD 
FACS tubes (BD, NJ, USA) containing 2% FBS/PBS. The cells were centrifuged at 1800 rpm for 3 
minutes and the supernatant was discarded. The cells were stained with antibodies for T cell lineage 
markers and their receptors. Briefly, 50ul of antibody cocktail was added into FACS tubes with 
resuspended cells and incubated at room temperature for 20 minutes in the dark with the following 
markers: CXCR5-APC; PD-1-BV421; CXCR4-PE-Cy5; CXCR3-PE-Cy7; CD4-BV605; CD25-FITC; 
CD127-PE; CD19-Alexa Flour 700 (BioLegend, CA, USA); Live/Dead aqua for Amcyan (Thermo 
Fisher Scientific, USA); CD3-APC-H7; CCR5-PerCp-Cy5.5; CCR6-BV650 (BD, NJ, USA). Cells 
were then washed with 150µl 2%FBS/PBS and centrifuged at 1800 rpm for 3 minutes after which 
supernatant was discarded. After final wash, an additional 150µl of 2% FBS/PBS was added to cells 
and 200µl of cell fix (BD, NJ, USA) was added to the cell suspension and stored at 4
o
C until flow 
cytometry.  
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Compensation for voltages and spillover of the antibody flourochromes were performed initially using 
PBMCs and subsequently, BD rainbow beads were used before acquiring samples to maintain and 
ensure accuracy. At least 100,000 events were acquired using a FACSDiva flow cytometer (BD 
Immunocytometry Systems). Gates differentiating negative and positive populations were set by FMO 
staining (Perfetto et al., 2004). Cell doublets were excluded using forward scatter-area versus forward 
scatter-height parameters and dead cells were excluded from the analyses. Flow cytometry data was 
analysed, and gating strategies and frequencies were established using the FlowJo v10 software (Tree 
Star, CA, USA). 
 
2.2.6 Statistical Analysis  
Descriptive statistics were used to compare demographic characteristics. Mann-Whitney U test was 
applied for non-parametric independent sample comparisons and Kruskal-Wallis (Nonparametric 
One-Way ANOVA) tests were used for non-parametric assessments of variation between groups. 
Spearman’s rank correlation (nonparametric correlation) was used to explore the relationship between 
immune cell subsets within individual cervical regions and across cervical regions. P values of <0.05 
were considered statistically significant. Statistical analyses were performed using GraphPad Prism 
version 7.03 (GraphPad Software, San Diego, CA, U.S.A.) and SAS version 9.3 (SAS Institute Inc., 
Cary). 
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2.3. Results 
2.3.1 Study demographics 
This study included 6 HIV-uninfected women undergoing elective hysterectomies (Table 2.1). All 
participants were black South African women, with a median age of 52.5 (47.3 – 58 years). Three of 
the women self-reported use of hormonal contraception to prevent unintended pregnancy or to control 
abnormal bleeding, while three did not use any form of hormonal contraceptives. Clinical reasons for 
hysterectomy varied, with half (3/6) of women with abnormal bleeding and the other half with 
multiple fibroids. Due to lack of vaginal swabs, this study could not screen for STIs and bacterial 
vaginosis.  
 
Table 2. 1. Study characteristics of the women undergoing elective hysterectomies 
Characteristics HIV Negative Women 
  n (%) 
N 6 
Age (years), median (IQR) 52.5 (47.3 -58) 
Hormonal Contraceptives  
 
DMPA 1 (16.7) 
Other (COC or NET-EN) 2 (33.3) 
Non-contraceptive users 3 (50) 
Reasons for hysterectomies 
 
Abnormal bleeding 3 (50) 
Multiple Fibroid uterus 3 (50) 
 
 
2.3.2. Gating strategy 
To define the abundance of local T and B cells in different regions within the human cervical tissue, 
this study optimized the gating strategy using both PBMCs and cervical tissues. Figure 2.1 
summarizes the gating strategy to identify activated T cell populations by flow cytometry. Cell 
doublets or aggregates were excluded by gating of singlets while live cells were distinguished into 
CD19+ B cell and CD3+ T cell populations. Live CD3+ T cell populations were further distinguished 
into CD4+ T cell populations. General expression of HIV co-receptors (such as CCR5 and CXCR4), 
inflammatory and regulatory (CCR6, CXCR3, CD25 CXCR5 and CD127) and markers of exhaustion 
(PD-1) were distinguished in CD4+ T cell population. Gates distinguishing negative and positive 
populations were defined by fluorescence minus one (FMOs) staining (Figure 2.2), where one 
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antibody of interest is left out of the panel in order to see which region would and would not have 
cells when the antibody is present or absent. 
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Figure 2. 1. The gating strategy used to identify activated T cell populations by flow cytometry. PBMC and genital tract MMCs were stained with 
fluorochromes-labelled monoclonal antibodies to define CXCR5-APC; PD-1-BV421; CXCR4-PE-Cy5; CXCR3-PE-Cy7; CD4-BV605; CD25-FITC; CD127-
PE; CD19-Alexa Flour 700; Live/Dead aqua for Amcyan; CD3-APC-H7; CCR5-PerCp-Cy5.5; CCR6-BV650–expressing populations.  
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Figure 2. 2. The fluorescence minus one (FMO) gating strategy. Gates distinguishing negative and positive populations were set by fluorescence minus one 
(FMO) staining, where samples were stained with all antibodies except the one of interest  
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2.3.3 Comparison of immune subsets in PBMCs and cervical tissue 
The frequency of B and T cells, including CD4+ T cell co-receptors in cervical tissues were 
compared to matching cells found in PBMC samples from HIV-uninfected women. Lymphocytes 
population (86% vs 27%, p = <0.0001) and the CD3+ cell expression (81% vs 11%, p = 0.001) were 
more abundant in the PBMCs compared to cervical tissues, respectively (Figure 2.3a). There was no 
significant difference in the proportion of CD19+ B cells in cervical tissues and PBMCs (4% vs 3%, 
p = 0.314). Focusing on the CD4+ T cell compartment (Figure 2.3b), the frequency of CD4+ T cells 
was significantly higher in PBMCs (65%) compared to cervical tissues (45%), p = 0.0009. 
Frequencies of CCR5 expression (38% vs 29%, p = <0.0001), CCR6 expression (63% vs 27%, p = 
<0.0001), CXCR3 expression (66% vs 20%, p = <0.0001), CXCR5 expression (19% vs 16%, p = 
<0.0001) by CD4+ T cells were significantly elevated in the cervical tissues compared to the 
PBMCs. CXCR4 expression by CD4+ T cells was more abundant in PBMCs than cervical tissues 
(97% vs 69%, p = 0.001). Compared to PBMCs, cervical CD4+ T cell population had elevated 
markers of T-regulatory cells CD25 (34% vs 5%, p = <0.0001) and exhaustion marker, PD-1(68% vs 
34%, p = <0.0001) but decreased secretion of CD127 (68% vs 89%, p = 0.001). 
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Figure 2. 3. Distribution of immune cell subsets in PMBCs and cervical tissues. The frequency of cervical tissue immune cell subsets (n=6) was 
compared with PBMCs of normal donors (n=2). A) shows primary immune cell subsets and B) shows CD4 cell subsets. Statistical significance 
represented as * (p <0.05).  
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2.3.4 Comparison of immune subsets in cervical tissue compartments 
This study defined the abundance and distribution of the major immune cells within the different 
regions of the cervix (Figure 2.4). Of the 6 participants recruited, only 4 had cervical tissue samples 
containing both endocervix and ectocervix while endocervix could not be determined in two 
participants. 
 
In the cervix, 11% of lymphocytes were CD3+ T cells and 3% were CD19+ B cells. Of the CD3+ T 
cell population, 45% were CD4+ T cells. This study did not measure CD8+ T cell populations but 
our assumption is that the remaining 55% belongs to CD8 T cell subset. Trifonova et al., (2014) 
showed that CD8 were the most abundant T cell population compared to CD4 cells in the cervix 
(Trifonova et al., 2014). No significant differences in frequency between immune cell subsets 
measured in the ectocervix versus the endocervix were found. The frequency of lymphocytes was 
similar in the ectocervix compared to the endocervix (31% vs 29%, p = 0.610). Similar numbers of 
CD3 cells were detected in ectocervix (10%) and endocervix (6%). When analysing the CD3+ T cell 
subsets, 48% of the CD4+ T cells were detected in the endocervix while 46% was found in the 
ectocervix. The overall frequency of B cells observed in both regions was very low, with 4% of 
CD19+ cells found in the endocervix and 2% in the ectocervix.  
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Figure 2. 4. Primary immune cell subset frequencies in the Ectocervix and Endocervix.  No 
significant differences were seen in frequencies of Lymphocytes, B cells and T cells 
between the two regions, however, observational trends were seen.  
 
2.3.5 Comparison of CD4+ T cell co-receptors in cervical tissue compartments  
To analyse the abundance of CD4+ T cell co-receptors in the cervix, we co-stained for CXCR4, 
CD127, CXCR3 and CCR6, CCR5, CD25 and PD1 (Figure 2.5). Overall, the majority of the CD4+ 
T cells the co-receptor expressed were CXCR4 (69%), followed by CD127 (67%), CXCR3 (66%) 
and CCR6 (63%). CCR5 was detected in 38%, while CD25 and PD1 were expressed in 34% of 
CD4+ T cells, respectively. None of these CD4+ T cells co-receptors were significantly different in 
the ectocervix and endocervix, with an exception of CCR6 and PD1 that showed a trended towards 
being elevated in the endocervix compared to ectocervix, p=0.067, respectively. Briefly, the median 
frequencies of CCR5 (50% vs 31%), CXCR4 (84% vs 78%), CCR6 (65% vs 54%, p = 0.067), 
CXCR3 (79% vs 61%), were slightly more abundant in the endocervix compared to ectocervix. The 
other abundant cells in the endocervix compared to ectocervix were regulatory T cells such as CD25 
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(48% vs 26%) and CD127 (75% vs 71%). Furthermore, frequency of exhausted CD4+ T cells, PD1, 
was more abundant in the endocervix (77%) than ectocervix (64%).  
Figure 2. 5. CD4+ cell in the ectocervix and endocervix. No significant difference was seen when 
comparing immune cell frequencies of CD4 receptor subsets between the two cervical regions.  
 
2.3.6 Hormonal Contraceptive did not influence frequencies of immune cell subsets in the 
cervical tissues 
The impact of hormonal contraceptives on the frequency of immune cells was determined by 
comparing immune cell subsets in women on HC versus those who were not. There was no 
difference in immune cell subsets when stratified according to HC use (HC users versus non-HC 
users) (Figure2.6a). Similarly, CD4+ co-receptors did not differ between the HC groups 
(Figure2.6b).
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Figure 2. 6. Frequencies of immune cell subsets in the human cervix. (A) Distribution of immune cells amongst HC users and non-HC users. (B) 
Distribution of CD4+ T cell co-receptors amongst HC users and non-HC user
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2.3.7 Relationship between CD4 T cell co-receptors in the ectocervix and endocervix 
A Spearman’s rank correlation test was used to assess an association between CD4 T cell co-
receptors in both the ectocervical and endocervical region. Table 2.2 represents the R and p values 
for immune cell subsets in both cervical regions. CD4+ T cells expressing CD25 were positively 
associated with CXCR4 chemokine receptor expression on CD4+ T cells (r = 0.817, p = 0.047) while 
CCR5 showed a trend towards a negative correlation with CD127 in the ectocervix (r = –0.789, p = 
0.062). Within the endocervix, CCR6 cells were positively associated with CD127 CD4+ T cells (r = 
0.954, p = 0.046). Similarly, CD127 and CD4+ T cells were also positively associated with PD1 (r = 
0.967, p = 0.033). Furthermore, CD25 showed a trend towards a negative correlation with CXCR3 
CD4+ cells in the endocervix (r = 0.942, p = 0.058). There was no significant correlation between 
cervical B and T cell subsets, data not shown. 
 
Table 2. 2. R and P values for the correlation of ectocervical and endocervical CD4+ T cell co-
receptor subsets. Significant associations shown in red. 
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2.4. Discussion 
Little is known about the abundance of local T and B cells in different regions within the human 
cervix. The current study determined the frequency and anatomical distribution of immune cell 
subsets in endocervical and ectocervical tissue sections of HIV uninfected women undergoing 
elective hysterectomies. This study found more T cell (CD3+ and CD4+ cells) populations in 
PBMCs compare to the cervical tissues.  Frequencies of CD19+ B cells were similar in the PBMCs 
and cervical tissues. Consistent with previous studies (McKinnon et al., 2011, Trifonova et al., 2014), 
this study showed that the expression of CD4+ T cell co-receptors were more pronounced in the 
cervical tissues compared to the PBMCs. Although there is no precise reason for the difference in 
immune cell population between blood and cervical mucosa, previous studies have suggested that 
target cells reside deeper within the sub-basal milieu and only migrate to the cervix when dendritic 
cells present exogenous antigen on MHC class I molecules, resulting in activation, proliferation and 
migration to the site of infection (Miller and Shattock, 2003). 
 
Comparing immune cell subsets in cervix, T cells (CD3+ cells) frequencies were higher compared to 
the B cells (CD19+ cells). When comparing the immune cell subsets in the endocervix and 
ectocervix, this study found differences in the distribution of B and T cells, with T cells being the 
most abundant. There were no significant differences seen in immune cells between the 
compartments and the lack of observed difference may be attributed to small sample size. Although 
the overall frequency of B cells was very low, CD19+ cells were twice as abundant in the ectocervix 
compared to the endocervix, consistent with previous reports (Trifonova et al., 2014). The lack of B 
cells in the cervical tissue may be due to the absence of infection as B cells are known to expand 
over the course of a primary infection (Hickey et al., 2011). Forty-five percent of CD3+ T cells in the 
cervical tissues were CD4+ T cells. No significant differences in frequency of CD4+ T cells 
measured in ectocervix versus endocervix were found. We did not measure CD8+ T cell populations, 
but it plausible to assume that the remaining unidentified population belongs to CD8 T cell subset. 
Although there is no significant difference in CD4+ T cells in the cervix, their presence in this site 
may lead to infection and pathogenesis in presence of a virus (Miller et al., 2005, Zhang et al., 1999). 
HIV infects the infiltrating CD4+ T cells in the cervical tissue and uses these to disseminate from the 
site of initial infection to other sites (Zhang et al., 1999, Miller et al., 2005). 
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As much as CD4 is the main cellular receptor for HIV entry, alone, it is not sufficient for HIV 
infection. Several chemokine receptors are needed to serve as co-factors that allow HIV entry when 
co-expressed with CD4 on a cell surface. These may include CXCR4, CXCR3, CCR6, and CCR5. 
With an exception of CCR6, this study did not find any difference in the proportions of the co-
receptors in the ectocervix and endocervix. CCR6 showed a trend towards being elevated in the 
endocervix compared to ectocervix. CD4+ T cells expressing CCR6 are identified as Th17 cells 
(Acosta-Rodriguez et al., 2007, Annunziato et al., 2012). Several studies have shown that Th17 cells 
are highly susceptible to HIV-infection and are depleted early from the cervix of HIV-infected 
patients (Sallusto et al., 2012, Weaver et al., 2013, Stieh et al., 2016). CCR6+ CD4+ T cells (Th17) 
play an important role in maintaining vaginal epithelial integrity, and their depletion may prompt 
genital inflammation that may further drive viral replication and facilitating HIV pathogenesis 
(Weaver et al., 2013, Stieh et al., 2016). This study cannot confirm whether CCR6+ CD4+ T cells 
found are Th17 due to the lack of transcriptional regulator RORγt that provides further evidence that 
these cells are specifically of the Th17 lineage. In contrast to other studies, this study observed a 
positive correlation amongst CD4+ T cell co-receptors and this may be attributed to small sample 
size.  
 
Another CD4+ T cell subsets measured in this study were T regulatory cells, such as CD25 and 
CD127, essential for the maintenance of self-tolerance (Sakaguchi et al., 1995). There was no 
significant difference in either CD25 or CD127 comparing the ectocervix and endocervix. Co-
expression of CD4+CD25+ cells may lead to increased HIV susceptibility in HIV uninfected 
individuals as these cells may be infected by HIV because they express HIV’s primary receptor 
(CD4) and co-receptors (CXCR4/CCR5). However, it is not known whether the infected 
CD4+CD25+ Treg cells die due to virus replication or remain effective as regulators (Nilsson et al., 
2006, Epple et al., 2006, Oswald-Richter et al., 2004). Increased CD127 levels are strongly 
associated with non-redundant mechanism of maintaining CD4 T cell survival and proliferation 
while decreased levels are linked to increased rate of disease progression, increased T-cell death 
resulting in CD4+ T-cell loss, and impairment of protective functional immunity (Schluns et al., 
2000, Chetoui et al., 2010, Fry and Mackall, 2005). Furthermore, this study found a slightly higher 
frequency of exhausted CD4+ T cells, PD1, in the endocervix than ectocervix. Increased levels of 
PD-1 are known to inhibit HIV-specific T cells in humans. Taken together, this suggests that 
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CD4+CD25+ and CD4+PD1+ T cells can mediate an environment that supports HIV survival and 
persistence by suppressing HIV-specific CD4+ T cells. 
 
Women using the long-acting injectable depot medroxyprogesterone acetate (DMPA) are reportedly 
at 2-fold increased risk for HIV infection from epidemiology studies, and at an increased risk of 
transmitting HIV to their sexual partners should they become infected (Baeten et al., 2007, Heffron 
et al., 2012, Martin et al., 1998, Morrison et al., 2010). The mechanisms by which injectable HCs 
might contribute to an increased risk of HIV-1 acquisition and transmission is through modulating 
recruitment of CD4+
 
T cells (Chandra et al., 2013). Thus we compared the availability of immune 
cell subsets in women using hormonal contraceptives to non-hormonal contraceptive users. There 
were no differences in frequencies of immune subsets (both B and T cells) amongst women on 
hormonal contraceptives versus non-hormonal contraceptive users. 
 
This study had several limitations including small sample size and lack of cervical tissues from 
younger women. To circumvent this in the future, we have extended the network of hospitals to 
improve the numbers of young women recruited to the study. Another limitation of this study was 
that we were unable to differentiate CD8 from CD3 T cell populations. We also focused only on the 
frequency and distribution of B and T cells and no other HIV target cells such as antigen presenting 
cells. This will be addressed in future studies, which will also include assessing the abundance of 
major lymphoid cells within the cervix and their localization in different anatomical regions. The 
possibility that the cervical tissue may have been in an inflamed state as a result of surgery or during 
laboratory processing could have influenced the frequency and distribution of immune cell subsets.. 
Furthermore, all women were of an advanced age (possibly post-menopausal), HIV uninfected, with 
unknown immune, BV and STI status, which could have altered the frequency and distribution of 
immune cell subsets. Future sample collection will include cervicovaginal swabs for cytokine, BV 
and STI screening and matching PBMCs for immunity. We will also collect information on clinical 
factors which might influence immune cell composition in the genital tract. These include sexual 
activity, vaginal insertion practices (such as the use of tobacco, snuff, savlon, which can alter the 
immunological environment of the genital tract) and use of intra-uterine devices.  
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In conclusion, we characterized the anatomical distribution of T and B cells, comparing different 
regions within the cervical tissue (endocervix and ectocervix). Endocervical tissue had slightly more 
immune CD4 T cell co-receptors compared ectocervical tissues. This suggests that the endocervical 
region might be associated with infectivity through an abundance of HIV target cells. Understanding 
the clinical links of the HIV susceptible immune cells in different regions of the cervix, as well as its 
influence in both HIV acquisition and in host defense against invading pathogens, may lead to novel 
strategies for HIV prevention and contribute to better women’s health.  
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Appendix E: Adult Consent Forms 
 
ADULT CONSENT FORM FOR ENROLMENT TO EXPLANT STUDY: 
ADMINISTRATIVE PAGE 
 
Please complete this administrative section prior to completing the consent form for enrolment. 
1. Has the participant completed the literacy assessment          Yes               No 
2. Does the participant require and impartial witness                Yes               No 
Staff Note: If the volunteer cannot read, the consent form must be read to the volunteer exactly as 
written, in the volunteer's language of choice, and a witness must sign this form to confirm that the 
correct information was given to the volunteer and that the volunteer freely consents to be in this 
study. 
If participant has indicated NO for both question do not proceed
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ADULT CONSENT FORM FOR ENROLMENT TO EXPLANT STUDIES: 
Version 1.1 
April 2014 
(Adults) 
 
PRINCIPAL INVESTIGATOR FOR EXPLANT STUDIES 
INHLOKO YOCWANINGO LWE EXPLANT 
Dr Derseree Archary 
CAPRISA, 2 nd Floor Doris Duke Medical Research Institute, 
Nelson R Mandela School of Medicine, Durban, South 
Africa 
E 031 260 4849 
Good day and thank you for taking the time to read this consent form or have it read to you! 
Sawubona, siyabonga ngokuthi uthathe isikhathi sakho ukufunda noma ukufundelwa incwadi 
yesivumelwano sokubamba iqhaza ocwaningwenil 
Introduction: 
Researchers at CAPRISA are trying to understand why some women become infected with HIV 
during sex while others do not. To help to understand how vaginal tissue protects women from HIV 
infection, we would like to study cervico-vaginal tissue to be able to show which part of the tissue 
provide protection. As you are an adult undergoing a planned elective hysterectomy, we would like 
to invite you to participate in this study by donating healthy tissue removed during your 
hysterectomy to our study. You do not have to agree to be part of this study and refusing 
participation will not impact on the quality of your treatment. I will give you information about this 
CAPRISA study and talk to you today about what your participation would involve and, if you agree 
to be part of this study, the procedures that you will undergo and what we wilt expect from you 
and what your rights are, 
Isingeniso: 
Abacwaningj base CAPRISA bazama ukuqonda ukuthi kunganj abanye abantu besifazane bethola 
igciwane lesandulela ngculazi ngokuya ocansini kuthi abanye bangalitholi. Ukusiza ekutheni siqonde 
ukuthi izicubu ezithize zesitho sangasese zibavikela kanjani labantu besifazane ekutholeni igciwane 
lesandulela ngculazi, sifuna ukucwanjnga ingxenyana yezicubu zesitho sangasese ukubona 
ukuthi iyiphi ingxenyana okuyiyona eyenza ukuthi bavikeleke. Njengoba ungowesifazane okhulile 
osethathe isinqumo sokukhipha isibeletho, siceJa ukukumema ukuthi ubambe iqhaza ocwaningweni 
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lwethu ngokuthi usiphe jzicubu zesibeletho lezi ezizokhishwa kuwena. Awuphoqelekile ukuthi 
ubambe iqhaza kulolucwaningo kanti ukunqaba angeke kushinsthe indlela ozophathwa ngayo. Uma 
uvuma ukubamba iqhaza kutolucwaningo Iwase CAPRISA,ngizokunika ulwazi kanye nemigomo 
okuzomele uyilandele, amalungelo akho kanye nezinto esizozilindela kuwe. 
You are asked to read (or have read to you) this consent form in the language of your choice. After 
you have read this consent form or have had the form read to you, please take your time in 
deciding if you wish to join this study and sign this form. Feel free to talk to people you trust such 
as your friends, family, or teachers if you feel you need help to decide to participate or not. This 
consent form may contain words or terms that you don't understand. Please ask me to explain 
anything you may not understand. To be sure you understand the contents of this form I will ask 
you a few questions after you have read this consent form or have had the consent form read to 
you. If you agree to join this study, we will ask you to sign this form. We wilt give you a copy of 
this form to keep or if you prefer we can keep this form for you. 
Uyacelwa ukuba ufunde (noma ufundelwe) ifomu lokuvuma ukubamba iqhaza ngolimu 
oluthandwa nguwe. Emva kokufunda lelifomu, sjcela uthathe isikhathi sakho ukucabanga ukuthi 
uyafuna yini ukubamba iqhaza na bese usayina lelifomu. Ungakhululeka ukukhuluma nabangani 
bakho obathembayo, umndeni, noma othishela uma udinga usizo ngokuthatha isinqumo. Lelifomu 
kungenzeka libe namagama ongawaqondisisi kahle. Ngicela ungibuze uma kukhona 
ongakuqondisisi kahie. Ukuze ngiqiniseke ukuthi uyayiqonda imininingwane yalelifomu 
ngizokubuza imibuzo embalwa emva kokuba usuljfundile noma walifundelwa. Uma uvuma 
ukubamba iqhaza sicela usayine lelifomu. Sizokunika elinye ifomu elifana naleli ozoljgcina noma 
sikugcinile thina.
60 
 
Background: 
Women are at greater risk of getting infected with HIV than men during heterosexual intercourse. 
For this reason, there is a Jot of research going on to develop strategies to reduce this risk in 
women. We recently completed a study where we were comparing the risk of HIV transmission in 
women who used a vaginal gel containing an active substance called Tenofovir at 1%, which is 
known to inactivate HIV, and women who used the gel but without this active substance, for up to 
12 hours before and after sexual intercourse. We showed that women who used the gel containing 
Tenofovir had a reduced risk of being infected with HIV. We also know that when women had a 
vaginal inflammation, they were at increased risk of getting infected with HIV. 
Esesikwazi: 
Abantu besifazane banamathuba amaningi okutheteleka ngegciwane lesandulela ngculazi uma 
kuqhathaniswa nabesilisa abenza ucansi nabesifazane ngesikhathi kwenziwa ucansi. Jngakho 
luluningi ucwaningo oluqhubekayo ukuzama izindiela zokwehlisa amathuba okutheleleka 
ngegciwane lesandutela ngculazi kubantu besifazane. Sisanda kuqeda ukwenza ucwaningo Japho 
sasibheka khona ukuthi ngabe uketshezi olune Tenofovir luyabavikela yini abesifazane kwigciwane 
lesanduleta ngculazi uma luqhathaniswa noketshezi olunengenayo iTenofovir uma lushuthekwa 
esithweni sangasese kuya emahoreni ayishumi nambili ngaphambi kokwenza ucansi kanye 
nasemuva kokwenza ucansi. Sabe sesikhombisa ukuthi uketshezi olune Tenofovir lwehlisa amathuba 
abesifazane okutheleleka ngegciwane lesandulela ngculazi. Siyazi nokuthí abesifazane abanesifo 
socansi banamathuba amaningj okutheleJeka ngegciwane lesandulefa ngculazi. 
We still do not fully understand the mechanism why increased inflammation leads to HIV infection 
and whether this inflammation will eventually impact the efficacy of tenofovir gel if it is licenced as 
means to prevent HIV infection in women. t will be talking to you about the study that CAPRISA will 
be undertaking to establish the role of inflammation in the effect of tenofovir gel to prevent HIV 
infection. 
Asikakatholi kahle ukuthj kungani ukuqhubeka kokuvuvuka nokushisa nobuhlungu 
kuleyondawana esithweni sangasese enegciwane elithile elingasilo elesandulela ngculazi noma 
leyondawo elimele noma enomuhuzuko ingaholela ekutholeni igciwane lesandulela ngcutazj, 
futhi ingabe lokukuvuvuka kungaba nomthelela ekusebenzeni koketshezj olune Tenofovir uma 
isitholakele imvume yokuthi loluketshezi lusetshenziswe. Ngizokhuluma nawe ngocwaningo 
esifuna ukulwenza eCAPRlSA 
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ukubheka indima edlawa xxxx ekusebenzeni koketshezi oJune Tenofovir ekuvikeleni igcjwane 
lesandueJJa ngculazi. 
Your participation in this study is voluntary: 
Before you learn more about the CAPRISA explant study, it is important that you know the 
following: 
• You do not have to take part in this study if you don't want to. 
• If you agree to take part but change your mind later about continued participation, you can do 
so. 
• If you decide not to take part in this study, it will not affect your access to services in your 
community or hospital. 
• If you decide not to take part in this study you will still be able to participate in the other 
studies in the future. 
Ukubamba kwakho iqhaza akuphoqelekile: 
Ukubamba kwakho iqhaza kulolucwaningo akuphoqelekile: 
Ngaphambi kokuba uzwe kabanzi ngalolucwaningo Iwase CAPRJSA, kubalulekile ukuthi wazi lokhu 
okulandelayo:  Awuphoqelekile ukubamba iqhaza kulolucwaningo 
• Uma uvuma ukubamba iqhaza kodwa ushintsha umqondo ngokuhamba kwesikhathi lokho 
kuvumelekile  Ukungabambi kwakho iqhaza kutolucwaningo ngeke kukuvimbe ukuthi uthole 
usizo lwezempilo emtholampilo wangakini noma esibhedieJa 
• Uma ungalibambi iqhaza kulolucwaningo uyovumeleka ukubamba iqhaza kolunye ucwaningo 
esingabanalo ngokuzayo 
The rest of this consent form will describe to you the purpose of CAPRISA explant study, when 
each study procedure wilt take place, procedures for contacting you if necessary, the risks and 
benefits of participating in this study, and your rights as a study participant. 
This study has been reviewed and approved by the University of KwaZulu-Natat's Biomedical 
Research Ethics Committee (BREC). 
Lencwadi yesivumelwano sokubamba iqhaza izokuchazefa kabanzi ngenhloso yocwaningo Iwase 
CAPRISA, ukuthi sizoluqhuba kanjani ucwaningo kanye nokuthi sizokuthinta kanjani, ubungozi 
kanye nenzuzo yokubamba iqhaza kanye namalungelo akho. 
Lolucwaningo lugunyazwe ikomidi Jezokuphepha kwezocwaningo lase nyuvesi yakwa Zulu-
Natal. 
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Purpose of CAPRISA explant study: 
The purpose of this study is to understand how vaginal tissue protects women from HIV infection and 
how the presence of sexually transmitted infections in this tissue can lower this protection against 
HIV. 
Inhloso yocwaningo lase CAPRISA: 
Inhloso yalotucwanjngo ukuqonda ukuthi kungani izicubu ezithize zesitho sangasese zivikela 
abesifazane ekutholeni igciwane lesandulela ngculazj kanye nokuthi ukuba khona kwezifo zocansi 
kulezizicubu kwehlisa amathuba okuvikeleka egciwaneni lesandulela ngculazi. 
CAPRISA Explant Study Procedures: 
After undergoing surgical hysterectomy, a section of your surgically removed tissue Will be taken to 
the CAPRISA laboratory jn Umbilo in an appropriate solution. In the laboratory, the tissue will be cut 
into smaller sections and tenofovir gel, other chemicals and HIV will be added to the tissue. We will 
then determine how your tissue responds to these conditions and blocks HIV infection. We will also 
store the tissue in order to see what immune cells are present in the tissue. This will give an idea of 
what happens in the female genital tract. 
You will not be able to participate in CAPRJSA explant study until all the consenting procedures 
relevant to your participation have been completed. You will be notified by study staff when the 
enrolment survey will take place. 
After you have agreed to be part of the CAPRISA explant study, you will sign the consent form. 
Imigudu ezolandelwa ukwenza ucwaningo le CAPRISA Explant 
Emva kokukhishwa kwesibeteletho, ingxenye yaso izothathwa ifakwe kwingxube ewuketshezi 
ihanjiswe esikhungweni sokucwaningo Iwamagazi esise CAPRISA. Esjkhungweni sokucwaninga 
igazi, izicubu zizosikwa zibencane bese zifakwa uketshezi lwe Tenofovir negciwane Jesandulela 
ngcuJaza kanye neminye imithi. Sizobe sesibheka ukuthi izicubu zirnelana kanjani nemithi esizifake 
yona. Izicubu eziyosala lapho ziyobe sezigcinwa kwenzela ukuthi sibuye siqhubeke nocwaningo. 
Lokhu kuzosinika umqondo wokuthi kwenzakalani esithweni sangasese somuntu wesifazane 
Angeke ukwazi ukubamba iqhaba kucwaningo Iwase CAPRISA anduba incwadi yesivumelwano 
sokubamba iqhaza isiqediwe. Uyokwaziswa uma sekufanele ucwaningo luqale Emva kokuba 
usuvumile ukubamba jqhaza ocwanjngweni Iwase CAPRISA uzosayjna incwadi yesivumelwano. 
Enrolment 
If you agree (consent) to participate in CAPRISA explant study and, if you are eligible to participate 
in this study: (1 ) you will be asked to provide a vaginal swab; (2) you will be asked to donate about 
2 tablespoons of blood (the trained nurse will take your blood). The swab and blood collected from 
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you will allow us to undertake some tests relating to your health. Your swab and blood specimens 
will be tested in the laboratory for sexually transmitted infections (STD. You will be tested for HIV 
by rapid antibody test. You will not be excluded from the study based on your HIV or STI results. 
We will then wait until the operation to collect the tissue samples. 
Ukungena ocwaningweni: 
Uma uvuma ukubamba iqhaza ocwaningweni Iwase CAPRISA, futhi uvumelekile: 
(1) Uyocelwa ukuba usiphe uketshezi lwesitho sakho sangasese 
(2) Uyocelwa ukuba usiphe izipuni ezimbiti zegazi (unesi uyothatha igazi). uketshezi negazi 
okuthathwe kuwe kuyosiza ukuthi senze ucwaningo mayelana nempilo yakho kuphinde 
kuyoxilongwa ukuthi akunazo yini izifo ezithathelana ngocansi negciwane lesandulela 
ngculazi. Awuzukhishwa ocwaningweni ngenxa yemiphumela yesandulela ngculazi kanye 
neye zifo ezithathelana ngocansi. Siyolinda ukuthi uhlinzwe kukhishwe izicubu. 
At enrolment when you are admitted to hospital in preparation for surgery, we will allocate to you a 
unique study number that we call a participant identification number (PID). This number will be our 
main reference to identify all specimens which we collect from you, including the hysterectomy 
sample. We will not link your name to your HIV test result or any of your other results and, 
therefore, when the study is carried out In the laboratory, we will onlyknow your PID number and 
not your name. We will not share your results with anyone and we will keep your results and 
number confidential. 
Uma sekuqala ucwaningo ususesibhedlela utindele ukuhlinzwa, sizokunikeza inombolo yakho 
ehlukile. Lenombolo iyona ezosetshenziswa kuwena kuphela ukuhlukanisa izicubu namagazi 
athathwe kuwe angahlangani nawabanye nanokuthi iziphi izicubu zesibeletho namagazi ezithathe 
kuwe. Angeke sihlanganise igama lakho kanye nemiphumeta yakho yegciwane lesandulela ngculazi 
kumbe nemjnye imiphumela yocwaningo, esikhungweni socwaningo Iwamagazi ngeke balibone 
igama lakho kodwa bayobona lenombolo esizokunika yona. Ngeke sikhombise muntu imiphumela 
yakhe kanye nenombolo yakho siyokugcina kuyimfihJo. 
Contact Procedures: 
After you have consented to participate in the study and samples have been collected, we will not 
have any followup contact with you again. However, you are allowed to contact us at any time after 
your operation to ask that we discard your tissue sample and not include you in our results. In this 
case, you will need to tell us the PID number that was allocated to you at enrolment. 
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Ukuxhumana. 
Emva kokuba usuvumile ukubamba iqhaza kulolucwaningo igazi nezicubu zakho ,sezithathiwe 
ngeke sisaphinde sixhumane nawe. Kodwa uvumelekile ukusithinta ernva kokuhlinzwa uma ufuna 
silahle zicubu zakho singabe sisazisebenzisa. Uma kunjalo kuyodingeka usitshele inombolo Jena 
esakunika yona 
Risks and/or discomforts: 
The study clinical procedures are similar to those experienced by women in routine gynecological 
examinations or during pre-assessment for elective hysterectomy. You may experience discomfort 
when having pelvic examinations and/or undergoing phlebotomy for this study. During phlebotomy, 
you may feel dizzy or faint, and/or develop a bruise or swelling where the needle is inserted. You 
may become embarrassed, worried, or anxious when completing the HIV-related interviews and/or 
receiving HIV/STI counseling. You may also become worried or anxious while waiting for the HIV 
test results or after receiving HIV-positive test results. Trained study staff will be available to help 
you deal with these feelings. 
Ubungozi kanye nobuhlungwana: 
Ukuxilongwa okuzokwenziwa kufolucwaningo kuyafana nalokho okwenziwa kubantu besifazane 
uma beya kudokotela wesifazane ukuyoxilongwa nokulungiselelwa ukukhishwa kwesibeletho. 
Kungenzeka uzwe ubuhlungwana uma kuxilongwa ingaphakathi lesitho sangasese sakho kanye 
noma uthathwa igazi - Ngesikhathi uthathwa igazi kungenzeka ube nesiyezi uhuzuke noma 
kuvuvukale lapho kade kufakwe khona inaliti. Kungenzeka uzenyeze, ukhathazeke noma ube 
nexhala ngesikhathi ubuzwa imibuzo mayelana negciwane lesandulela ngculazi kanye nezifo 
zocansi. Kungenzeka ube nexhala ngesikhathi usalinde imiphumela yakho yegciwane lesandulela 
ngculazi noma emva kokuba uthole imiphumela ekhombisa ukuthi unegciwane lesandulela 
ngculazi. Abasebenzi abawufundele umsebenzi bazobe bekhona ukukusiza ukuthi ubhekane 
nemizwa yakho 
Benefits: 
You and others may benefit in the future from information learned in this study. You will have 
access to free counselling and testing for HIV and sexually transmitted infections and other HIV 
risk reduction- If you are infected with HIV or have an STI, you witl be referred for medical care, 
counselling, and other services and research studies available to you. If you are HIV positive you 
will have access to care and anti-retroviral treatment if indicated. You may speak with a study 
counsellor who may help with questions about the study and your health at any time or as needed. 
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All care provided to you in the context of this study will be in accordance with Department of 
Health Policies and Guidelines. 
lnzuzo: 
Wena kanye nabanye abantu nizozuza ngolwazi esizolufunda kulolucwaningo. Nizothola 
ukwelulekwa nokuhlolelwa igciwane lesandutela ngculazi kanye nokuhlolelwa izifo zocansi 
ezithathelanayo kanye nokuthi unganciphisa kanjani amathuba okutheleleka ngegcjwane 
lesanduJela ngculazi mahhala. Uma ngabe usunegciwane lesandulela ngculazi noma isifo socansi 
uyodluliselwa emtholampiJo lapho uzothola khona usizo, tokwelulekwa. Uma unegciwane 
lesandulela ngculazi uyosizwa ngokuthi uthole imishanguzo nokunakekelwa kwezempilo. 
Ungakhuluma nomeluleki ozobe eyingxenye yocwaningo ongakusiza urna unemibuzo mayelana 
nocwaningo kanye nangempilo yakho. Lonke unakekelo lwezempilo oyoluthola kulolucwaningo 
luyobe luhambisana nemigomo yomnyango wezempilo. 
New findings: 
The findings from this study will be published in journals that you or other members of the public 
can access. Your information will not be revealed in such publications 
Imiphumel emisha: 
Imiphumela yalolucwaningo iyokhishwa emaphepheni umphakathj ozokwazi ukufinyelela kuwo. 
Imininingwane yakho ngeke ivezwe kulawo maphepha. 
 
Reasons why you may be withdrawn from the study without your consent: 
You may be removed from the study without your consent for the following reasons: 
• The study is cancelled by the University of KwaZulu-Natal 
Biomedical Research Ethics Committee (BREC).  Other 
administrative reasons. 
Kungenzeka ukhishwe kucwaningo ngaphandle kokuthi waziswe ngaiezizizathu elizandelayo• 
• Uma ucwaningo luvalwa yiNyuvesi yaKwaZutu-Natali  Kanye 
nezinye izizathu zokuphatha 
Costs to you: 
There is no cost to you for taking part in this study. At the enrolment you will receive R50 for 
participating in this study, 
Ukukhokha: 
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Awuzukhokha lutho ngokubamba kwakho iqhaza kulolucwaningo. Uma sekuqala ucwaningo 
uyonikweza R50 ngokubamba kwakho iqhaza. 
Confidentiality: 
All information you share with us will be maintained securely with limited access by 
CAPRISA study staff, and you will only be identified using a PID. Personal information from 
your records will not be released without your written permission. You will not be personally 
identified in any publication or information shared publicly about this study. Your records 
may be reviewed by the BREC or study sponsors. 
Secondly, information that the study staff get from you, your tissue samples will be 
confidential in most situations. This means that study staff will NOT tell your parent or 
guardian about results or procedures that you have the right to decide on your own about. 
Imfihlo: 
Yonke imininingwane osinikeze yona iyobekwa abasabenzi base CAPRISA endaweni 
evikelekile lapho kungangeni khona noma ubani, kuyobe sekusetshenziswa inombolo yakho 
esizokunika yona. Imininingwane yakho ngeke idalulwe ngaphandåe kwemvume yakho 
ebhatwe phansi. Ngeke udalulwe uma sikhipha ulwazi locwaningo sitshela umphakathi. 
Imininingwane yakho kungenzeka icutshungulwe abaxhasi bocwaningo. 
Okwesibili, imininingwane yakho kanye nezicubu eziyothathwa kuwe abasebenza 
ocwaningweni ziyoba imfihlo ngasosonke isikhathi. Lokho kusho ukuthi ngeke kutshelwe 
urnzali noma umbheki wakho ngemiphumela uwena kuphela ongabatshela. 
Research-Related Injury: 
Based on the procedures we propose to undertake in this study and described above it is unlikely 
that you will be injured as a result of being in this study. 
Ukulimala okuhambisana nocwaningo: 
Ngenxa yemigudu esizoyilandela kulofucwaningo nesesikuchaze ngenhla mancane amathuba 
okuthi ungalimala ngenxa yalolucwaningo. 
Problems or Questions about participating in this research study: 
If you ever have any questions about your participation in this study you should contact Dr 
Derseree Archary at 031-260 4849 or 0739797212, CAPRISA, Second Floor Doris Duke 
Medical Research Institute, Durban, 359 King George V Avenue, Glenwood, Durban, South 
Africa. If you have questions about your rights as a research participant, you should contact 
the Chairperson of the Biomedical Research Ethics Committee of the University of 
KwaZulu-Natal at in Durban using the address below: 
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Research Office 
Biomedical Research Ethics Administration 
Westville Campus, Govan Mbeki Building 
Private Bag X 54001 
Durban 
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za 
Website: https: //research. ukzn. ac-za/ResearchEthics/Biomedica Research Ethics. aspx 
tzinkinga kanye 
Uma unemibuzo ngokubamba kwakho iqhaza kulolucwaningo ungathintha u dokotela Derseree 
Archary kulenamba 031 260 4849 noma 0739797212 CAPRISA Second Floor Doris Duke Medical 
Research Institute, Durban, 359 King George V Avenue, Glenwood, Durban, South Africa.Uma 
unemibuzo ngamalungelo akho njengombambiqhaza, ungathinta usihlabo we Biomedical Research 
Ethics Committee of the University of KwaZuJu-Natal eThekwini kulelikhe'i elingenzansi: 
Research Office 
Biomedical Research Ethics Administration 
Westville Campus, Govan Mbeki Building 
Private Bag X 54001 
Durban 
4000 
KwaZulu-Natal, SOUTH AFRICA 
Tel: 27 31 2604769 - Fax: 27 31 2604609 
Email: BREC@ukzn.ac.za 
Website: https//research.ukzn.ac.za/ResearchEthics/BiomedicalReseaarchEthics
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SIGNATURE PAGE: 
If you have read the informed consent (or if you have had it read to you) and understand the 
information, and you voluntarily agree to join this study, please complete the comprehension 
assessment with the staff member. If you have a good understanding of what you are agreeing 
to participate in, you will be asked to please sign your name below. 
 
 Volunteer's name Volunteer's signature Date 
(print name as it appears in ID 
b
o
o
k]Birth certificate) 
 
Witness' name (print) Witness' signature Date 
 
Was a copy of the signed copy given to the volunteer: Yes          No If no, 
why not: 
 
 
Name of staff member who 
administered consent (print) 
Staff members signature Date 
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Appendix F: CAPRISA PID data capture form 
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Appendix G: Explant protocol 
 
Purpose 
This protocol describes the method used to quantify data for all immune cells including lymphocytes 
and antigen presenting subtypes and for setting up tissue explant cultures. 
 
Background 
The immune cells present in the human genital tract are important for protection from sexually 
transmitted infections and can be a target of viral infections, such as HIV. Therefore, knowledge 
about the distribution and variability of the different immune cell types is important for understanding 
the susceptibility to infections and the development of prevention strategies against infection. Thus, 
human cervical explant tissue can be used effectively to quantify data for all immune cells including 
lymphocytes and antigen presenting subtypes. In addition, tissue explant cultures offer the best bridge 
between in vitro testing and in vivo experimentation. Several explant culture set-ups have currently 
been published. This protocol describes the polarized cervical explant cultures. These cultures can be 
used to evaluate microbicide product toxicity, effectiveness, and product application times. This can 
be used to investigate HIV-1 pathogenesis and include but are not limited to testing innate 
antimicrobial activity of human secretions, the influence of cytokines, semen and hormones on HIV-1 
infection, the cell types that are infected after exposure to HIV-1, and the migration of infected cells 
from the tissues. 
 
Preparation 
Biological hood should be decontaminated using 70% ethanol at least 15 minutes prior to use.  
Be sure to follow all Good Clinical Laboratory Practice (GCLP) guidelines. 
Surgical tools should be sterile autoclaved. 
Waste container with disinfectant should be ready for any disposable materials.  Be sure to prevent 
overflow. 
Prepare all media according to appropriate instructions. 
 
Storage Requirements 
All media should be stored at 2-8°C and brought to room temperature before use.  
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Procedure 
1) Day 1:  
 Do checklist (see- appendix 1A) 
 Prepare transport media (R15 and can be stored at 40C for 2weeks maximum): 
 RPMI     225ml 
 10% FBS     25ml 
 100x Pen/Strep/L-glutamine  2.5ml 
 2.5µg/ml Amphotericin B (Fungizone) 2.5ml 
 
Before you leave for the day: Check if the temperature of the of the incubator is set at 37
0
C and CO2 
is at 5% 
 
2) Day 2:  
 
1. Check if the temperature of the of the incubator is set at 370C and CO2 is at 5% 
2. Make FRESH 13mL Collagenase Digestion Media per patient 
a. Remove Collagenase IV vial from -20oC. 
b. Carefully measure 0.2g of collagenase powder per subject. 
c. Reseal vial, store in desiccators at -20 oC. 
d. In 15mL conical tube add collagenase powder, then add 2ml of HBSS  
e.  Vortex well to mix, until powder has completely dissolved, making sure no 
clumps get stuck on the walls or cap. 
f. Filter solution with 0.22 μm Millipore filter. 
g. Collagenase Digestion Media expires one day from preparation. ****Always 
make up fresh Collagenase Digestion Media for use**** 
 
3) Cervical Explant set-up 
 
1. Tissue processing 
1) Tissue should be put in transport medium (R15) immediately after surgery and 
transported to the laboratory within 3 hours from collection. 
2) In the Petri dish, rinse tissue with new transport media (R15) or PBS and keep the 
tissue in solution at all times to tissue drying out. 
3) Trim excessive muscular tissue with surgical tools (Scalpels, forceps), being sure 
to limit handling of the epithelial layer.  
4) Separate the different sections of the tissue (endocervix and ectocervix) carefully. 
To do this, use a scalpel, a pair of forceps that can easily grab the tissue, and a 
blunt pair of forceps to hold the tissue in place while cutting (you may want to 
start with another person holding the tissue until you have become accustomed to 
this procedure).  When using the forceps, make sure not to puncture the epithelial 
layer. Afterward, discard the connective tissue into a biohazard bin. 
a. Punch 3mm biopsies of epithelial layer. Using a scalpel, slice excess 
muscular tissue behind the epithelium so that each explant is about 2mm 
thick.   
b. Experiment conditions should be performed in duplicate (if possible), 
therefore attempt to extract an even number of explants. 
 
For Distribution of cells: 
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1. Transfer 10 x 3mm3 pieces (further cut into small pieces for effective digestion) of 
endocervical or ectocervical explant tissue into the gentleMACS C tube containing 
Digestion Media (40µl Collagenase solution + 8ml R10 (appendix 1B) + 8µl DNAse) 
2. Tightly close the C tube and attach it upside down onto the sleeve of the gentleMACS 
Dissociator 
3. Run gentleMACS Program m_spleen_01.  
4. After termination of the program, detach C Tube from the gentle MACS Dissociator. 
5. Incubate the sample for 30 minutes at 37 °C on a shaker platform at low speed 
(approximately 120 rpm). 
6. Attach C Tube upside down onto the sleeve of the gentle MACS Dissociator 
7. Run gentleMACS Program m_spleen_01. 
8. (Optional) Centrifuge sample at 1800rpm for 1 minute. 
9. Apply the cell suspension to a cell strainer (100 μm mesh size) placed on a 50 mL tube.  
10. Rinse strainer with 30 mL R10 medium and collect the flow-through. 
11. Centrifuge at 1800rpm and 4 °C for 5 minutes. 
12. Discard supernatant 
 
Staining 
13. Re-suspend the pellet (with whatever left in the well) and transfer the liquid with cells 
(~200ul) to a V bottom plate  
14. Count cells (optional) 
15. Prepare the surface stain Master Mix (see - Appendix 1C) 
16. Spin the plate at 1800rpm for 3 min and discard supernatant 
17. Add 50µl of surface stain master mix per well  
18. Incubate surface stain for 20 mins at room temp in the dark (Cover with foil)  
a. While waiting, prepare compensation beads (see –Appendix 1D) 
19. Wash cells with 150µl of PBS-1 (99µl PBS + 1µl FBS, multiply this by number of wells) 
20. Centrifuge at 1800 rpm for 3 mins and discard supernatant 
21. Wash cells with 200µl of PBS-1 into each well 
22.  Centrifuge at 1800 rpm for 3 mins and discard supernatant 
23. Resuspend cells in 200ul of 1x cell fix and transfer to Facs tubes 
24. Optional, add additional 150µl of PBS-1 into each well 
25. Cover with foil and store at 4oC, if not acquiring the same day 
26. Acquire cells for Flow Cytometry (cover your other tubes with foil while acquiring) 
 
 
Checklist 
Equipment and Materials  
1. 2-8°C Refrigerator 
2. -80°C freezer 
3. 5% CO2 incubator at 37°C 
4. Plate Reader 
5. Vacuum 
6. Pipette Aid 
7. Pipettes – range 20, 200, 1000µl 
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8. Waste container  
9. Sharps container 
10. brass cork bore 
11. Sterile surgical tools 
a. Forceps 
b. Blunt nose scissors 
 
Disposables 
1. Pipette tips – range 1, 10, 20, 200, 1000µl 
2. 10ml serological pipettes  
3. Petri dish 
4. Scalpel 
5. Biopsy Punch tool – 2mm 
6. gentleMACS C tube 
7. MACS Dissociator 
8. 0.22 μm Millipore filter 
 
Reagents and Consumables 
1. Transport media per explant (R15) 
a. RPMI                                22.5ml 
b. 10% FBS                 2.5ml 
c. 100x Pen/Strep/L-glutamine               125ul 
d. 2.5µg/ml Amphotericin B (Fungizone)             250ul 
 
2.  Collagenase Solution per patient 
a. Collagenase powder                0.2g 
b. HBSS                 2ml 
 
3. Collagenase Digestion Media  
a. R10 media               8ml 
b. Collagenase Solution               40µl 
c. DNase                8µl 
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Appendix H: R10 Medium 
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Appendix I: Surface marker flow panel and PBMC staining 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Antibodies purchased from BD Science (Scientific group) and Biolegend  
 
Compensation Tubes 
1. Set up during one of the incubation/wash steps during staining procedure 
2. Compensation tubes should never be prepared more than 1hr before flow analysis 
Label compensation tubes as follows: 
a) Add 2ml of PBS-1 to a FACS tube and label it as Unstained  
b) Add 6 drops of anti-mouse IgG compensation beads (both positive and negative).  
c) Mix well and transfer 120ul of this mixture to all individual tubes  
d) Add 2ul of the appropriate antibody to each tube. Mix  
e) Incubate at RT for 5min  
f) Top up to 300ul of PBS-1 to each tube  
g) Store at 4oC no more than 1 hour prior to flow analysis  
 
 
 
 
 
Marker Flourochromes VOLUME/ REACTION(50UL 
TOTAL) 
CXCR5  APC 1 
Live/Dead Amcyan 3 
PD-1 BV421 1 
CXCR4 PE-Cy5 1 
CXCR3 PE-Cy7 1 
CD3 APC-H7 1 
CD4 BV605 1 
CD25 FITC 1 
CD127 PE 1 
CD19 Alexa Flour 700 1 
CCR5 PerCP-Cy5.5 1 
CCR6 BV650 1 
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Appendix J: PMBC isolation and staining protocol  
One day before lab work prepare and gather all reagents: 
Ficoll 
R10 
2% FBS PBS 
FACS tubes 
Falcon 50ml tubes 
Serological pipettes 
Tube racks 
Centrifuge with correct buckets 
Pipette tips 
Antibodies 
PBMC isolation in the morning 
1) Spin acd tubes containing blood for 10min at 1600rpm (no brakes) 
 
2) While spinning add 12ml of Ficoll to 50ml tube  
 
3) Once tubes have spun mark the plasma layer at top and bottom making sure to leave a little 
bit of plasma 
 
4) Using a serological pipette remove the plasma layer and replace with 2% FBS-PBS 
 
5) Mix by pipetting up and down with the serological pipette  
 
6) Layer the blood onto the Ficoll at an angle using the serological pipette drop by drop 
 
7) Once the blood is layered on the Ficoll (make sure there is no blood in the Ficoll layer) Spin 
the 50ml tube for 30 min at 1400rpm (no brakes) 
 
8) While the tube is spinning prepare the Antibody cocktail 
9) After spinning remove the plasma layer (leave a bit in case PBMCs are in) with a serological 
pipette and discard.  
 
10) Take PMBCs with a little bit of plasma and Ficoll (if the pmbcs are in the Ficoll take the 
Ficoll but avoid RBCs) 
 
11) Place PBMCs in a new 50ml conical tube and add 40ml of 2%FBS-PBS and spin at 1600rpm 
for 10min (PBS washes away the Ficoll and plasma) 
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12)  After spin decant the S/N and flick out pellet into remaining media. 
 
13)  Add 10ml of R10 media 
 
14)  Counting cells: 50ul cells and 50ul trypan blue and mix in a tube and count cells in 2 grids  
 
#cells (cells/ml) = cells counted/2 x df (1) x 10^4: answer must be in millions 
 
15)  Go back to 50ml containing cells and R10 and spin at 2000rpm for 6min and decant S/N then 
add R10 at 1ml per million cells (eg 2million cells = 2ml R10) 
 
16)  Check how many tubes needed for the experiment 
 
PBMC staining 
17)  Divide the cells equally amongst tubes and calculate the number of cells in each tube (cells 
must be in million units) 
 
18)  Spin tubes for 6 min at 2000 rpm and decant S/N 
 
19)  Add 2%FBS-PBS at 1ml per million cells 
 
20)  Spin tubes at 2000rpm for 6min and decant S/N 
 
21)  Add 50ul Ab cocktail to each tube 
 
22)  Incubate tubes with foil for 20 min at 4oC 
 
23)  After incubation wash cells with 2%FBS-PBS at 1ml per mil cells  
 
24)  Spin tubes at 2000rpm for 6min  
 
25)  If acquiring same day, decant and add PBS + 1 before acquiring cell 
 
26) If acquiring next day, decant add cell fix at 1ml per million cells and store at 4oC in the dark. 
